Anastrozole vs Gonadorelin
A side-by-side research comparison of Anastrozole and Gonadorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Anastrozole | Gonadorelin |
|---|---|---|
| Full name | Anastrozole (Arimidex) | Gonadorelin (GnRH Analog) |
| Category | Hormone Replacement | Hormone Replacement |
| Status | FDA-approved prescription | FDA Approved |
| Mechanism | Selectively and reversibly inhibits aromatase (CYP19A1), the enzyme that converts androgens to estrogens. Reduces circulating estradiol levels without affecting other steroid pathways. | Binds GnRH receptors on pituitary gonadotrophs to stimulate LH and FSH release, maintaining testicular/ovarian function and natural sex hormone production. |
| Molecular weight | 293.37 Da | 1182.39 Da |
| Half-life | ~46.8 hours | ~10-40 minutes |
| Bioavailability | ~80-85% oral | ~90% subcutaneous |
| Typical dose | 0.25-0.5 mg | 100-500 mcg |
| Frequency | 2-3x per week | 2-3x per week or pulsatile |
| Route | Oral tablet | Subcutaneous injection |
Anastrozole reported benefits
- Estrogen control
- Reduced water retention
- Prevention of gynecomastia
- Maintained testosterone ratio
- Improved body composition
Gonadorelin reported benefits
- Maintains natural hormone production
- Fertility preservation
- Testicular function support
- LH/FSH normalization
Related comparisons
Research and educational reference only. Not medical advice.